Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.

Panatto D, Amicizia D, Lai PL, Cristina ML, Domnich A, Gasparini R.

Indian J Med Res. 2013 Dec;138(6):835-46. Review.

2.

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group.

Lancet. 2013 Mar 9;381(9869):825-35. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

PMID:
23324563
3.

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

Morley SL, Cole MJ, Ison CA, Camaraza MA, Sotolongo F, Anwar N, Cuevas I, Carbonero M, Campa HC, Sierra G, Levin M.

Pediatr Infect Dis J. 2001 Nov;20(11):1054-61.

PMID:
11734711
4.

Serogroup B meningococcal vaccines.

Zimmer SM, Stephens DS.

Curr Opin Investig Drugs. 2006 Aug;7(8):733-9. Review.

PMID:
16955685
5.

The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.

Mameli C, Galli E, Mantegazza C, Fabiano V, Zuccotti GV.

Future Microbiol. 2015;10(10):1579-98. doi: 10.2217/fmb.15.91. Epub 2015 Oct 6. Review.

PMID:
26437903
6.

Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.

Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM.

Vaccine. 2015 Jul 31;33(32):3850-8. doi: 10.1016/j.vaccine.2015.06.079. Epub 2015 Jun 30.

PMID:
26141011
7.

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

Noronha CP, Struchiner CJ, Halloran ME.

Int J Epidemiol. 1995 Oct;24(5):1050-7.

PMID:
8557439
8.

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil.

de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, Gattas VL, Vasconcelos Hde G, et al.

Lancet. 1992 Oct 31;340(8827):1074-8. Erratum in: Lancet 1992 Dec 19-26;340(8834-8835):1554. Gral IM [corrected to Landgraf IM].

PMID:
1357461
9.

Meningococcal B Vaccination (4CMenB) in Infants and Toddlers.

Esposito S, Tagliabue C, Bosis S.

J Immunol Res. 2015;2015:402381. doi: 10.1155/2015/402381. Epub 2015 Aug 17. Review.

10.

Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

Esposito S, Castellazzi L, Bosco A, Musio A, Stoddard J.

Immunotherapy. 2014;6(4):395-408. doi: 10.2217/imt.14.11. Review.

PMID:
24815780
11.

[Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].

Levy C, Taha MK, Bingen E, Cohen R; Groupe des Pédiatres et Microbiologistes de l’Observatoire National des Meningites Bactériennes de l’Enfant.

Arch Pediatr. 2012 Sep;19 Suppl 2:S49-54. doi: 10.1016/S0929-693X(12)71273-3. French.

PMID:
22883366
12.

Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.

Carter NJ.

BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. Review.

PMID:
23575646
13.

Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, Kieninger D, Prymula R, Dull P, Ypma E, Toneatto D, Kimura A, Pollard AJ; European MenB Vaccine Study Group.

JAMA. 2012 Feb 8;307(6):573-82. doi: 10.1001/jama.2012.85.

PMID:
22318278
14.

A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.

Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.

Vaccine. 2015 May 15;33(21):2500-10. doi: 10.1016/j.vaccine.2015.03.001. Epub 2015 Mar 17.

PMID:
25795256
15.

Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.

Patel M, Lee CK.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001093. Review.

PMID:
15674874
17.

[Study progress on serogroup B meningococcal vaccine].

Shao ZJ, Li YX.

Zhongguo Yi Miao He Mian Yi. 2009 Dec;15(6):542-6. Review. Chinese.

PMID:
20518335
18.

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK.

Vaccine. 2013 Feb 4;31(7):1113-6. doi: 10.1016/j.vaccine.2012.12.022. Epub 2012 Dec 20.

PMID:
23261039
19.

Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil.

Cardoso CW, Pinto LL, Reis MG, Flannery B, Reis JN.

Vaccine. 2012 Aug 10;30(37):5541-6. doi: 10.1016/j.vaccine.2012.06.044. Epub 2012 Jun 27.

20.

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).

Gandhi A, Balmer P, York LJ.

Postgrad Med. 2016 Aug;128(6):548-56. doi: 10.1080/00325481.2016.1203238. Epub 2016 Jul 7. Review.

PMID:
27467048

Supplemental Content

Support Center